MARKET

EXEL

EXEL

Exelixis Inc
NASDAQ
36.95
-0.03
-0.08%
Closed 19:59 05/13 EDT
OPEN
37.00
PREV CLOSE
36.98
HIGH
37.19
LOW
36.24
VOLUME
3.15M
TURNOVER
--
52 WEEK HIGH
40.26
52 WEEK LOW
20.14
MARKET CAP
10.08B
P/E (TTM)
20.99
1D
5D
1M
3M
1Y
5Y
1D
Exelixis raises 2025 revenue guidance by $100M amid strong CABOMETYX market share gains and new NET approval
Seeking Alpha · 8h ago
Closing Bell Movers: Exelixis up 6% on earnings beat
TipRanks · 10h ago
Stocks to Watch: American Eagle Outfitters, Exelixis, Everus Construction, Grail
Dow Jones · 10h ago
Exelixis initiated dose-escalation stage of first human Phase 1 study of XB628
TipRanks · 11h ago
Exelixis (EXEL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
NASDAQ · 11h ago
Exelixis Sees Higher Demand for Flagship Cancer Drug -- Market Talk
Dow Jones · 12h ago
Exelixis stock up on guidance raise, results beat
Seeking Alpha · 12h ago
Exelixis Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters · 12h ago
More
About EXEL
More
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Recently
Symbol
Price
%Change

Webull offers Exelixis Inc stock information, including NASDAQ: EXEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXEL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EXEL stock methods without spending real money on the virtual paper trading platform.